TNSN07071A1 - Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases - Google Patents

Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases

Info

Publication number
TNSN07071A1
TNSN07071A1 TNP2007000071A TNSN07071A TNSN07071A1 TN SN07071 A1 TNSN07071 A1 TN SN07071A1 TN P2007000071 A TNP2007000071 A TN P2007000071A TN SN07071 A TNSN07071 A TN SN07071A TN SN07071 A1 TNSN07071 A1 TN SN07071A1
Authority
TN
Tunisia
Prior art keywords
inhibitors
aminohetero
kinases
pyrazole
protein
Prior art date
Application number
TNP2007000071A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Lee Andrew Funk
Lei Jia
Pei-Pei Kung
Jerry Jialun Meng
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677463&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07071(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN07071A1 publication Critical patent/TNSN07071A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Il est proposé des composés de formule (I), Ainsi que des procédés pour leur synthèse et leur utilisation. Les composés préférés sont de puissants inhibiteurs de la protéine-kinase c-Met et sont utiles dans le traitement de troubles comportant une croissance cellulaire anormale, tels que les cancers.
TNP2007000071A 2004-08-26 2007-02-23 Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases TNSN07071A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60524404P 2004-08-26 2004-08-26
US69080305P 2005-06-14 2005-06-14
PCT/IB2005/002695 WO2006021881A2 (fr) 2004-08-26 2005-08-15 Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase

Publications (1)

Publication Number Publication Date
TNSN07071A1 true TNSN07071A1 (fr) 2008-06-02

Family

ID=35677463

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000071A TNSN07071A1 (fr) 2004-08-26 2007-02-23 Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases

Country Status (44)

Country Link
US (1) US20060128724A1 (fr)
EP (1) EP1784396B8 (fr)
JP (1) JP4167295B2 (fr)
KR (1) KR100869393B1 (fr)
CN (1) CN101018780B (fr)
AP (1) AP2332A (fr)
AR (1) AR050529A1 (fr)
AT (1) ATE492544T1 (fr)
AU (1) AU2005276132B2 (fr)
BR (1) BRPI0514537B8 (fr)
CA (1) CA2577937C (fr)
CR (2) CR8938A (fr)
CY (1) CY1111138T1 (fr)
DE (1) DE602005025499D1 (fr)
DK (1) DK1784396T3 (fr)
EA (1) EA011725B1 (fr)
EC (1) ECSP077278A (fr)
ES (1) ES2355923T3 (fr)
GE (1) GEP20094845B (fr)
GT (1) GT200500226A (fr)
HK (1) HK1105415A1 (fr)
HN (1) HN2005000477A (fr)
HR (1) HRP20110116T1 (fr)
IL (1) IL181045A0 (fr)
MA (1) MA28827B1 (fr)
ME (1) ME01309B (fr)
MX (1) MX2007002310A (fr)
MY (1) MY139942A (fr)
NI (1) NI200700058A (fr)
NL (1) NL1029809C2 (fr)
NO (1) NO338656B1 (fr)
NZ (1) NZ552946A (fr)
PA (1) PA8643201A1 (fr)
PE (1) PE20060651A1 (fr)
PL (1) PL1784396T3 (fr)
PT (1) PT1784396E (fr)
RS (1) RS51601B (fr)
SI (1) SI1784396T1 (fr)
SV (1) SV2006002208A (fr)
TN (1) TNSN07071A1 (fr)
TW (1) TWI300411B (fr)
UY (1) UY29080A1 (fr)
WO (1) WO2006021881A2 (fr)
ZA (1) ZA200701281B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009063A (es) * 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
EA013678B1 (ru) 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
DK1959955T3 (da) * 2005-12-05 2011-02-07 Pfizer Prod Inc Fremgangsmåde til behandling af abnorm cellevækst
CA2632283C (fr) * 2005-12-05 2011-06-21 Pfizer Products Inc. Polymorphes d'un inhibiteur de c-met/hgfr
ES2393130T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Triazoles bicíclicos como moduladores de proteínas quinasas
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
NZ577611A (en) 2006-12-14 2012-01-12 Bayer Schering Pharma Ag Dihydropyridine derivatives useful as protein kinase inhibitors
CA2675755C (fr) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine et derives de pyridazine en tant qu'inhibiteurs de kinase
DK2076289T3 (da) 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
KR101586503B1 (ko) 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
WO2009053737A2 (fr) 2007-10-25 2009-04-30 Astrazeneca Ab Dérivés de pyridine et de pyrazine - 083
EP2265270A1 (fr) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
KR101034351B1 (ko) * 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
ES2551899T3 (es) 2008-06-19 2015-11-24 Xcovery Holding Company Llc Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de cinasas
EP2356116A1 (fr) * 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
US8269012B2 (en) * 2009-05-28 2012-09-18 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CA2780922A1 (fr) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC Derives de la 7-aminofuropyridine
ES2509951T3 (es) * 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
WO2011109593A1 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC 5-aminopyrrolo/pyrazolopyridines substituées
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
EP2588107A1 (fr) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
WO2012003544A1 (fr) * 2010-07-09 2012-01-12 The Walter And Eliza Hall Institute Of Medical Research Inhibiteur de protéine kinases et méthodes de traitement
CN101967140A (zh) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 氘代克里唑蒂尼及其衍生物、制备方法和应用
CA2813607C (fr) 2010-10-08 2021-08-31 Xcovery Holding Company, Llc Composes substitues de pyridazine carboxamide
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
AU2012236834B2 (en) 2011-03-28 2015-12-10 Mei Pharma, Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
CA2842841C (fr) * 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Molecules spirocycliques convenant comme inhibiteurs de proteines kinases
RU2014102935A (ru) 2011-08-02 2015-09-10 Пфайзер Инк. Кризотиниб для применения в лечении рака
EP2758387A4 (fr) * 2011-09-21 2015-03-11 Teligene Ltd Composés de pyridine comme inhibiteurs de kinases
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
EP2822953B9 (fr) 2012-03-06 2017-06-21 Pfizer Inc Dérivés macrocycliques pour le traitement de maladies prolifératives
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2013138210A1 (fr) * 2012-03-14 2013-09-19 Ning Xi Composés cycliques substitués et procédés d'utilisation
CN104334545A (zh) 2012-03-16 2015-02-04 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
WO2013144191A1 (fr) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh 2-amino-3-cyanopyridines substituées utilisées comme inhibiteurs de l'échange sodium-calcium et leurs utilisations dans le cas de maladies cardiovasculaires
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
CN106349222B (zh) * 2012-04-22 2019-03-05 东南大学 克里唑替尼前药及其制备方法与用途
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
WO2013181251A1 (fr) 2012-05-29 2013-12-05 Ratiopharm Gmbh Sel de chlorhydrate de crizotinib sous forme cristalline
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014020467A2 (fr) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Procédé de préparation de composés d'aminohétéroaryle à substitution pyrazole
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014033136A1 (fr) 2012-08-27 2014-03-06 Cemm - Research Center For Molecular Medicine Of The Austrian Academy Of Sciences Composés aminohétéroaryles en tant qu'inhibiteurs de mth1
CN103720691A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
WO2014081816A1 (fr) * 2012-11-21 2014-05-30 Concert Pharmaceuticals, Inc. Dérivés fluorés de composés amino-hétéroaryle substitués par pyrazole
BR112015016395A2 (pt) * 2013-01-18 2017-07-11 Hoffmann La Roche pirazóis 3-substituídos e uso como inibidores de dlk
PT2952510T (pt) * 2013-02-02 2019-04-16 Centaurus Biopharma Co Ltd Inibidor de proteína-cinase de 2-aminopiridina substituída
CN103992307B (zh) 2013-02-16 2017-07-14 浙江九洲药物科技有限公司 一种克里唑替尼的制备方法
WO2014139391A1 (fr) * 2013-03-11 2014-09-18 Teligene Ltd Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970131B1 (fr) 2013-03-14 2017-11-15 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970220A2 (fr) 2013-03-14 2016-01-20 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR102158756B1 (ko) 2013-03-14 2020-09-23 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
EP2970137A1 (fr) 2013-03-14 2016-01-20 Epizyme, Inc. Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
CN104059054B (zh) * 2013-03-19 2018-11-20 浙江导明医药科技有限公司 用于治疗癌症的三级环状胺alk激酶抑制剂
WO2014203177A1 (fr) * 2013-06-18 2014-12-24 Shilpa Medicare Limited (r)-3-[1-(2,6-dichloro-3-fluorophényl)méthoxy]-5-[1-(pipéridin-4-yl)-1h-pyrazol-4-yl]pyridine-2-amine amorphe
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
KR101598664B1 (ko) 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
WO2015034729A1 (fr) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Composés de pyridine substituée et leurs méthodes d'utilisation
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CA2923533C (fr) 2013-09-30 2019-08-06 Korea Research Institute Of Chemical Technology Derives de triazolopyrazine et ses utilisations
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2015172747A1 (fr) * 2014-05-16 2015-11-19 Zhaoyin Wang Molécules spirocycliques servant d'inhibiteurs de mth1
CA2955676A1 (fr) 2014-08-25 2016-03-03 Pfizer Inc. Combinaison d'un antagoniste de pd-1 et d'un inhibiteur d'alk dans le traitement du cancer
WO2016044576A1 (fr) * 2014-09-17 2016-03-24 Epizyme, Inc. Sels, co-cristaux, formes amorphes, et formes cristallines d'un inhibiteur d'arginine méthyltransférase
CN104402868B (zh) * 2014-11-04 2016-08-24 郑州泰基鸿诺医药股份有限公司 氘代克里唑蒂尼晶型及其制备方法
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
WO2016106309A1 (fr) 2014-12-23 2016-06-30 Axikin Pharmaceuticals, Inc. Inhibiteurs de 3,5-diaminopyrazole kinase
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
WO2016145383A1 (fr) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Inhibiteurs de mth1 pour le traitement de maladies
WO2016169504A1 (fr) 2015-04-24 2016-10-27 广州再极医药科技有限公司 Dérivé pyrimidylamino à cycle condensé, son procédé de préparation, et intermédiaire, composition pharmaceutique et applications associées
CN106279112A (zh) * 2015-06-12 2017-01-04 浙江九洲药业股份有限公司 一种克里唑替尼中间体及其制备方法和应用
CA3000386A1 (fr) 2015-09-30 2017-04-06 Merck Patent Gmbh Combinaison d'un antagoniste de la liaison de l'axe pd-1 et d'un inhibiteur de alk dans le traitement du cancer alk-negatif
KR102369735B1 (ko) 2016-05-20 2022-03-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 암을 치료하기 위한 면역요법과의 글루타메이트 조정제의 용도
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
WO2018217787A1 (fr) 2017-05-23 2018-11-29 Mei Pharma, Inc. Polythérapie
EP3668507A4 (fr) 2017-08-14 2021-05-12 MEI Pharma, Inc. Polythérapie
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
KR102207608B1 (ko) 2019-04-24 2021-01-26 윤종오 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2129663C (fr) * 1992-02-06 2005-07-05 James S. Huston Proteine fixatrice biosynthetique pour marqueur du cancer
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CA2259222A1 (fr) * 1996-06-27 1997-12-31 Pfizer Inc. Derives de 2-(2-oxo-ethylidene)-imidazolidin-4-one et leur utilisation comme inhibiteurs de la farnesyl-proteine-transferase
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
SK2442001A3 (en) * 1998-08-27 2002-10-08 Pfizer Prod Inc Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
CA2341739C (fr) * 1998-08-27 2005-07-12 Pfizer Products Inc. Derives de quinolin-2-one utiles en tant qu'agents anticancereux
EP1006113A1 (fr) * 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
US6586447B1 (en) * 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1081137A1 (fr) * 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
DK1106612T3 (da) * 1999-11-30 2004-05-17 Pfizer Prod Inc Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2005526026A (ja) * 2002-02-06 2005-09-02 イシウム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ イエルサレム カテコール生物学的等価体
JP2005538975A (ja) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
AU2003247141A1 (en) * 2002-08-01 2004-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE10307845A1 (de) * 2003-02-25 2004-09-02 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
MXPA05009063A (es) * 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
EA013678B1 (ru) * 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
UY29080A1 (es) 2006-03-31
MX2007002310A (es) 2007-05-08
TWI300411B (en) 2008-09-01
AR050529A1 (es) 2006-11-01
US20060128724A1 (en) 2006-06-15
EP1784396B1 (fr) 2010-12-22
WO2006021881A3 (fr) 2006-05-18
EP1784396A2 (fr) 2007-05-16
NL1029809C2 (nl) 2006-10-17
JP2008510788A (ja) 2008-04-10
DK1784396T3 (da) 2011-02-14
RS51601B (en) 2011-08-31
IL181045A0 (en) 2007-07-04
PE20060651A1 (es) 2006-07-19
JP4167295B2 (ja) 2008-10-15
PA8643201A1 (es) 2006-06-02
ZA200701281B (en) 2008-12-31
DE602005025499D1 (de) 2011-02-03
TW200621751A (en) 2006-07-01
GEP20094845B (en) 2009-11-25
CA2577937A1 (fr) 2006-03-02
EA011725B1 (ru) 2009-04-28
CN101018780B (zh) 2012-01-11
PT1784396E (pt) 2011-01-27
AU2005276132A1 (en) 2006-03-02
ATE492544T1 (de) 2011-01-15
WO2006021881A2 (fr) 2006-03-02
EA200700321A1 (ru) 2007-08-31
BRPI0514537A (pt) 2008-06-17
ES2355923T3 (es) 2011-04-01
SV2006002208A (es) 2006-10-04
BRPI0514537B8 (pt) 2021-05-25
SI1784396T1 (sl) 2011-03-31
EP1784396B8 (fr) 2011-04-20
CN101018780A (zh) 2007-08-15
NZ552946A (en) 2010-09-30
MA28827B1 (fr) 2007-08-01
CY1111138T1 (el) 2015-06-11
GT200500226A (es) 2006-04-10
CA2577937C (fr) 2010-12-21
AP2332A (en) 2011-12-05
NL1029809A1 (nl) 2006-02-28
ME01309B (me) 2013-12-20
CR20120421A (es) 2012-09-14
HN2005000477A (es) 2010-06-09
ECSP077278A (es) 2007-03-29
BRPI0514537B1 (pt) 2020-05-12
AP2007003906A0 (en) 2007-02-28
HRP20110116T1 (hr) 2011-03-31
NO338656B1 (no) 2016-09-26
NI200700058A (es) 2008-03-07
CR8938A (es) 2007-08-14
NO20071320L (no) 2007-05-29
HK1105415A1 (en) 2008-04-03
AU2005276132B2 (en) 2011-09-29
KR100869393B1 (ko) 2008-11-21
MY139942A (en) 2009-11-30
PL1784396T3 (pl) 2011-05-31
KR20070038569A (ko) 2007-04-10

Similar Documents

Publication Publication Date Title
TNSN07071A1 (fr) Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
AP1649A (en) Triamide-substituted heterobicyclic compounds.
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TN2009000551A1 (fr) Nouveaux composes chimiques
HUP0203509A2 (hu) Triciklusos pirazolkarbonsav-származékok, a vegyületek előállítása és a vegyületeket tartalmazó gyógyászati készítmények
EA200700711A1 (ru) Производные бензимидазолуксусной кислоты, проявляющие антагонизм в отношении рецептора crth2, и их применение
JP2015527349A (ja) 免疫関連及び炎症性疾患の治療
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
HK1048990A1 (en) Novel compounds.
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
HUP9800417A2 (hu) 5-Szubsztituált-3-(1,2,3,6-tetrahidro-piridin-4-il)-1H-indolok és 5-szubsztituált-3-(piridin-4-il)-1H-indolok, alkalmazásuk mint új 5-HT agonisták, a vegyületeket tartalmazó gyógyszerkészítmények
YU84603A (sh) Novi inhibitori tirozin kinaze
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.